NEW YORK, Dec. 13 /PRNewswire/ -- STORY SUMMARY: THIS IS A MULTIVU REPORT.
MORE THAN 15 MILLION AMERICANS ARE DIAGNOSED WITH ATOPIC DERMATITIS, COMMONLY REFERRED TO AS ECZEMA. THE CHRONIC INFLAMMATORY DISEASE THAT AFFECTS 90 PERCENT OF PATIENTS WITHIN THE FIRST FIVE YEARS OF THEIR LIVES, IS CHARACTERIZED BY RED, DRY, ITCHY SKIN THAT RASHES. THIS UNCOMFORTABLE AND UNPLEASANT CONDITION LARGELY AFFECTS CHILDREN, BUT CAN ALSO AFFECT ADULTS AND OFTEN LEADS TO SLEEP INTERRUPTION DUE TO THE SEVERITY OF THE ITCH.
WHILE MANY PRODUCTS TO TREAT ECZEMA ARE CURRENTLY AVAILABLE, THE FDA HAS RECENTLY CLEARED A NEW APPROACH IN MANAGING THE SIGNS AND SYMPTOMS OF ECZEMA CALLED MIMYX CREAM.
DR. JOSEPH FOWLER, CLINICAL PROFESSOR OF DERMATOLOGY, UNIVERSITY OF LOUISVILLE:
“Unlike current therapies for eczema, MimyX Cream offers a new approach to managing atopic dermatitis. MimyX provides a dual function that repairs the skin’s barrier and relieves the signs and symptoms of eczema. This new therapy essentially mimics the natural components of the skin and has been shown to be clinically safe and effective.”
FOR MORE INFORMATION ON MIMYX CREAM, CALL 1-800-724-1565. I’M DANIELLE ADDAIR. IMPORTANT SAFETY INFORMATION
MIMYX CREAM IS INDICATED TO MANAGE AND RELIEVE THE BURNING AND ITCHING EXPERIENCED WITH VARIOUS TYPES OF DERMATOSES, INCLUDING ATOPIC DERMATITIS, ALLERGIC CONTACT DERMATITIS AND RADIATION DERMATITIS. MIMYX CREAM IS CONTRAINDICATED IN PATIENTS WITH KNOWN HYPERSENSITIVITY TO ANY OF THE COMPONENTS OF THE FORMULATION. IN RADIATION THERAPY, MIMYX CREAM MAY BE APPLIED AS INDICATED BY THE TREATING RADIATION ONCOLOGIST. DO NOT APPLY 4 HOURS PRIOR TO A RADIATION SESSION. MIMYX CREAM DOES NOT CONTAIN A SUNSCREEN AND SHOULD NOT BE USED PRIOR TO EXTENDED EXPOSURE TO THE SUN. FOR EXTERNAL USE ONLY.
ADDITIONAL RESOURCES: Audio version and more available at http://www.prnewswire.com/broadcast/23015/consumer.shtml
AUDIO PROVIDED BY: Stiefel Laboratories
Audio: Note to Editor - Press Only - includes Audio, MP3 requests,contact information and more available athttp://www.prnewswire.com/broadcast/23015/press.shtmlStiefel Laboratories
CONTACT: For story information, please call MultiVu, 800-653-5313, ext. 3or email radio@multivu.com
